199 related articles for article (PubMed ID: 37782515)
21. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
22. Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
Rosenstein I; Axelsson M; Novakova L; Malmeström C; Blennow K; Zetterberg H; Lycke J
J Neurol; 2023 Oct; 270(10):4800-4811. PubMed ID: 37314506
[TBL] [Abstract][Full Text] [Related]
23. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
24. Differentiating societal costs of disability worsening in multiple sclerosis.
Ness NH; Schriefer D; Haase R; Ettle B; Cornelissen C; Ziemssen T
J Neurol; 2020 Apr; 267(4):1035-1042. PubMed ID: 31848738
[TBL] [Abstract][Full Text] [Related]
25. Disability progression
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
27. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
28. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
J Neurol; 2024 Apr; ():. PubMed ID: 38668889
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity.
Ransohoff RM
Trends Immunol; 2023 Apr; 44(4):266-275. PubMed ID: 36868982
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
31. Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
Pfeuffer S; Wolff S; Aslan D; Rolfes L; Korsen M; Pawlitzki M; Albrecht P; Havla J; Huttner HB; Kleinschnitz C; Meuth SG; Pul R; Ruck T
Neurology; 2024 Jul; 103(2):e209574. PubMed ID: 38870471
[TBL] [Abstract][Full Text] [Related]
32. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
35. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
36. Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Durozard P; Zaaraoui W; Ranjeva JP; Pelletier J; Audoin B
J Neurol Neurosurg Psychiatry; 2024 May; ():. PubMed ID: 38719433
[TBL] [Abstract][Full Text] [Related]
37. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E; Schmitz S; Tubridy N; Walsh C; Barry M
Mult Scler Relat Disord; 2016 Sep; 9():23-30. PubMed ID: 27645339
[TBL] [Abstract][Full Text] [Related]
39. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
